Managing Chemotherapy Toxicity

Documents to Request

• CTCAE v5.0 reference for the specific adverse event term
• Current and prior cycle lab results (CBC with differential, CMP, LFTs)
• Regimen-specific dose modification tables from the protocol or NCCN guidelines
• Nursing flow sheets with vital signs and symptom documentation
• Prior toxicity grading documentation from previous cycles
• Supportive care medication list with doses and schedule
• Relevant imaging if toxicity involves organ damage (e.g., chest CT for pneumonitis)
• Clinical trial protocol dose modification section if applicable

Step 1: Grade the Adverse Event Using CTCAE v5.0

CTCAE v5.0 grades adverse events on a 1–5 scale:

Critical grading examples for common toxicities:

• Neutropenia: Grade 1 (ANC <LLN–1500), Grade 2 (1000–1500), Grade 3 (500–1000), Grade 4 (<500)
• Thrombocytopenia: Grade 1 (75,000–LLN), Grade 2 (50,000–75,000), Grade 3 (25,000–50,000), Grade 4 (<25,000)
• Nausea: Grade 1 (loss of appetite, intake preserved), Grade 2 (decreased oral intake), Grade 3 (inadequate caloric/fluid intake, hospitalization)
• Peripheral neuropathy: Grade 1 (asymptomatic, reflexes decreased), Grade 2 (moderate symptoms, limiting instrumental ADL), Grade 3 (severe, limiting self-care ADL)
• Diarrhea: Grade 1 (increase 4 stools/day over baseline), Grade 2 (increase 4–6 stools/day), Grade 3 (increase ≥7 stools/day, hospitalization), Grade 4 (life-threatening, urgent intervention)

Use the exact CTCAE v5.0 term — do not paraphrase or use institutional shorthand.

Step 2: Apply Dose Modification Rules

Standard dose modification framework (apply protocol-specific rules when available):

Agent-specific dose modification highlights:

• Capecitabine: reduce to 75% for Grade 2 hand-foot syndrome, hold for Grade 3
• Cisplatin: hold for CrCl <60 mL/min; no dose reduction — discontinue and substitute carboplatin if nephrotoxicity persists
• Anthracyclines: monitor cumulative dose (doxorubicin max 450–550 mg/m²); hold for LVEF drop >15% from baseline or LVEF <45%
• Taxanes: hold for ANC <1500; reduce one dose level for Grade 3 neuropathy

Step 3: Implement Supportive Care Interventions

Hematologic toxicity management:

• G-CSF (filgrastim, pegfilgrastim) for febrile neutropenia risk >20% or secondary prophylaxis after prior febrile neutropenia episode
• Platelet transfusion threshold: <10,000 for prophylaxis, <50,000 for active bleeding or procedures
• Erythropoiesis-stimulating agents (ESAs) only for chemotherapy-induced anemia with Hgb <10, palliative intent

Gastrointestinal toxicity management:

• Antiemetic regimen per NCCN emetogenic risk (high: NK1 antagonist + 5-HT3 + dexamethasone ± olanzapine; moderate: 5-HT3 + dexamethasone; low: dexamethasone or 5-HT3 alone)
• Loperamide for uncomplicated diarrhea; octreotide for Grade 3–4 or persistent diarrhea
• Mucositis: cryotherapy during bolus 5-FU; palifermin for autologous SCT conditioning with TBI

Neurotoxicity management:

• Duloxetine for established chemotherapy-induced peripheral neuropathy (CIPN) — the only agent with ASCO Level 1 evidence
• Dose modification is the primary prevention strategy for CIPN
• No evidence supports calcium/magnesium infusions for oxaliplatin CIPN prevention

Step 4: Document and Communicate Toxicity Management Decisions

For each graded adverse event, document:

1. CTCAE v5.0 term and grade
2. Date of onset and current status (improving, stable, worsening)
3. Relationship to treatment (definite, probable, possible, unlikely)
4. Action taken (dose held, reduced, discontinued, supportive care added)
5. New dose level if modified (document in mg/m² and absolute dose)
6. Plan for reassessment prior to next cycle
7. Communication to referring providers and primary care

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is each adverse event graded using the exact CTCAE v5.0 term and grade definition?
2. Do dose modifications follow protocol-specific rules (or standard guidelines if no protocol)?
3. Is supportive care aligned with NCCN supportive care guidelines for the specific toxicity?
4. Are cumulative dose limits tracked for agents with lifetime maximums (anthracyclines, bleomycin)?
5. Is the plan for next-cycle reassessment clearly documented?

Quality Audit

• CTCAE v5.0 version explicitly referenced (not v4.03 or earlier)
• Each adverse event uses the correct MedDRA preferred term from CTCAE
• Grade assignment matches the v5.0 grading criteria verbatim
• Dose modification level documented in both percentage and absolute dose
• Baseline values available for comparison (labs, imaging, symptoms)
• G-CSF use aligned with NCCN Hematopoietic Growth Factors guideline
• Antiemetic regimen matches NCCN Antiemesis emetogenic risk category
• Cumulative anthracycline dose tracked against maximum
• Attribution (relationship to treatment) documented for each event
• Clinical trial protocol-specific rules applied when applicable
• Patient education on expected toxicities documented
• Communication with referring providers documented
• Follow-up plan and timeline for reassessment specified

Guidelines

• Use CTCAE v5.0 exactly — grading definitions changed between v4.03 and v5.0 for several common terms
• Grade at the worst severity within the reporting period, not at the time of assessment
• Never reduce dose for Grade 1 toxicity unless protocol-specifically mandated
• Febrile neutropenia (ANC <500 + fever ≥38.3°C single or ≥38.0°C sustained) is always at minimum Grade 3 and requires immediate intervention
• Dose re-escalation after reduction is generally not recommended — maintain reduced dose for subsequent cycles
• Track total number of dose reductions; more than two reductions for the same toxicity typically warrants regimen change discussion
• Document patient-reported outcomes alongside clinician-graded CTCAE — they frequently diverge
• Immune-related adverse events from checkpoint inhibitors use CTCAE grading but require separate management algorithms (see managing-immunotherapy-protocols skill)